Avoro Capital Advisors LLC - 22 Nov 2021 Form 4 Insider Report for CymaBay Therapeutics, Inc.

Role: 10%+ Owner
Signature: Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer
Issuer symbol: N/A
Transactions as of: 22 Nov 2021
Net transactions value: +$9,999,750
Form type: 4
Filing time: 23 Nov 2021, 15:15:27 UTC
Next filing: 30 Jan 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CBAY	Pre-funded Warrant (right to buy)	Purchase	$9,999,750	+2,500,000		$4.00	2,500,000	22 Nov 2021	Common Stock	2,500,000	$0.000100	See footnotes	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after November 22, 2021, exercise the Pre-funded Warrant until it has been exercised in full.
F2	The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
F3	The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.